A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples